Fig. 2.

MET treatment induces a time-related increase in the amount of FC RELN and GAD₆₇ but not GAD₆₅ promoter immunoprecipitated with MeCP2 antibody. RELN, GAD₆₇, and GAD₆₅ promoter fragments were immunoprecipitated with MeCP2 antibody and were quantified by using competitive PCR with internal standards (25). Depicted are the ratios between the amount of RELN (□), GAD₆₇ (■), and GAD₆₅ (●) promoters immunoprecipitated with MeCP2 antibody (MeCP2-ChIP) and the amount of the corresponding promoter fragments in the initial nonimmunoprecipitated extract (input). MET was given at dose of 5.2 mmol/kg s.c. twice a day; the last injection of MET was administered 2 h before decapitation. The data represent the mean ± SE of three to five mice. ∗, P < 0.01 when 0- and 3-day are compared with 6- and 15-day MET-treated groups (ANOVA followed by Dunnett's test).